MedTrace Logo

Treatment of Acute Pancreatitis With Ketorolac

NCT02885441 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-05-15

No results posted yet for this study

Summary

Patients with acute pancreatitis will be randomly assigned in either study group to receive oral (injection) Ketorolac or the control group. In patients who cannot tolerate oral medications, ketorolac injection will be used.

Conditions

Interventions

DRUG

Ketorolac

Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.

Sponsors & Collaborators

  • Ilam University of Medical Sciences

    lead OTHER

Principal Investigators

  • Shaahin Shahbazi, MD · Head of Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-02-01
Completion
2019-02-01

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885441 on ClinicalTrials.gov